XNAS
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | — | 0.43 | — | $388,744 | — | +0.18% | -19.30% | — |
| 2026-03-31 | Q4 2025 | — | -1.16 | — | $91,728 | — | +4.72% | -2.99% | -9.84% |
| 2025-11-14 |
| Q3 2025 |
| — |
| -1.56 |
| — |
| $203,371 |
| — |
| — |
| — |
| — |
Showing last 3 quarters.